Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980925570> ?p ?o ?g. }
- W2980925570 endingPage "5051" @default.
- W2980925570 startingPage "5051" @default.
- W2980925570 abstract "Introduction: 5-azacytidine and decitabine have been widely studied as first line chemotherapy in acute myeloid leukemia (AML) patients not eligible for allogenic stem cell transplantation, but data on their use as salvage chemotherapy are limited. We tried to define efficacy and feasibility of hypometilating agents (HMA) as salvage chemotherapy in patients without previous allogenic stem cell transplantation. Methods: We retrospectively reviewed clinical records of 35 patients treated with HMA as salvage therapy in our 5 institutions since their introduction in clinical practice for AML patients. Results: Median age was 68 years. 22 patients were men and 13 women. One patient was AML with t(9;11), 18 were AML MRC, 4 were therapy related AML, 12 were AML NOS. Two patients were favorable risk sec ELN 2017, 20 were intermediate, 11 were adverse risk. Cytogenetic risk was not available for 2 patients. 66% of patients received HMA as second line therapy for their disease, 23% as third line and 11% were beyond the third line. 29 patients were treated with azacitidine and 6 with decitabine. Six patients reached CR or morphologic leukemia free state (MLFS) or PR after HMA. All patients underwent intensive chemotherapy (i.e. FLAI or 3+7 like) as first line induction, and we excluded patients who had an HMA as first line chemotherapy and another one as second line. Median number of hospitalization days during HMA therapy was 11(1-78); median number of HMA cycles was 3 (range 1-31). 7 episodes of sepsis demonstrated by positive blood cultures and 3 fungal infections were recorded during HMA therapy. Median OS was 197 days from the starting of HMA and median EFS was 125 days. Median EFS in patients with adverse cytogenetic risk was 68 days, while median EFS in patient with favorable and intermediate risk was 207 days (p=0,0124). Median OS in patients with adverse cytogenetic risk was 181 days, while median OS in patient with favorable and intermediate risk was 307 days (p=0,0401).We did not find significant difference between median OS ed EFS in patients with refractory disease compared to relapsed patients. 31% of patients with adverse cytogenetic risk reached a stable disease with HMA therapy while 64% of patients with favorable/intermediate cytogenetic risk reached a response (CR, PR; MLFS) or a stable disease. We did not find significant differences between transfusion needs before and after salvage therapy but this could be due to the small size of our sample. Conclusion: HMA showed efficacy and a considerable OS in our patients. OS was significantly better in favorable/intermediate risk patients than adverse risk patients. Hospitalization was limited, and we can argue that this could lead to improved costs and quality of life, but further studies are needed. So HMA could be a good clinical option in a selected population of relapsed patients, especially in those not suitable for allogenic bone marrow transplantation, in whom the prognosis is generally extremely poor. Further studies are needed to define if there is a survival or quality of life advantage over other therapies. Disclosures No relevant conflicts of interest to declare." @default.
- W2980925570 created "2019-10-25" @default.
- W2980925570 creator A5003619706 @default.
- W2980925570 creator A5017931505 @default.
- W2980925570 creator A5020636005 @default.
- W2980925570 creator A5029007744 @default.
- W2980925570 creator A5031590759 @default.
- W2980925570 creator A5033585629 @default.
- W2980925570 creator A5039467121 @default.
- W2980925570 creator A5044624520 @default.
- W2980925570 creator A5054730102 @default.
- W2980925570 creator A5087722204 @default.
- W2980925570 date "2017-12-07" @default.
- W2980925570 modified "2023-09-26" @default.
- W2980925570 title "Hypometilating Agents (HMA) As Salvage Therapy in Relapsed or Refractory AML: A 5-Center Retrospective Study" @default.
- W2980925570 doi "https://doi.org/10.1182/blood.v130.suppl_1.5051.5051" @default.
- W2980925570 hasPublicationYear "2017" @default.
- W2980925570 type Work @default.
- W2980925570 sameAs 2980925570 @default.
- W2980925570 citedByCount "0" @default.
- W2980925570 crossrefType "journal-article" @default.
- W2980925570 hasAuthorship W2980925570A5003619706 @default.
- W2980925570 hasAuthorship W2980925570A5017931505 @default.
- W2980925570 hasAuthorship W2980925570A5020636005 @default.
- W2980925570 hasAuthorship W2980925570A5029007744 @default.
- W2980925570 hasAuthorship W2980925570A5031590759 @default.
- W2980925570 hasAuthorship W2980925570A5033585629 @default.
- W2980925570 hasAuthorship W2980925570A5039467121 @default.
- W2980925570 hasAuthorship W2980925570A5044624520 @default.
- W2980925570 hasAuthorship W2980925570A5054730102 @default.
- W2980925570 hasAuthorship W2980925570A5087722204 @default.
- W2980925570 hasConcept C104317684 @default.
- W2980925570 hasConcept C121332964 @default.
- W2980925570 hasConcept C126322002 @default.
- W2980925570 hasConcept C141071460 @default.
- W2980925570 hasConcept C142424586 @default.
- W2980925570 hasConcept C143998085 @default.
- W2980925570 hasConcept C150194340 @default.
- W2980925570 hasConcept C185592680 @default.
- W2980925570 hasConcept C190727270 @default.
- W2980925570 hasConcept C197934379 @default.
- W2980925570 hasConcept C2776239401 @default.
- W2980925570 hasConcept C2776694085 @default.
- W2980925570 hasConcept C2778041864 @default.
- W2980925570 hasConcept C2778336483 @default.
- W2980925570 hasConcept C2778461978 @default.
- W2980925570 hasConcept C2778729363 @default.
- W2980925570 hasConcept C2780235182 @default.
- W2980925570 hasConcept C2780775027 @default.
- W2980925570 hasConcept C2911091166 @default.
- W2980925570 hasConcept C55493867 @default.
- W2980925570 hasConcept C71924100 @default.
- W2980925570 hasConcept C87355193 @default.
- W2980925570 hasConceptScore W2980925570C104317684 @default.
- W2980925570 hasConceptScore W2980925570C121332964 @default.
- W2980925570 hasConceptScore W2980925570C126322002 @default.
- W2980925570 hasConceptScore W2980925570C141071460 @default.
- W2980925570 hasConceptScore W2980925570C142424586 @default.
- W2980925570 hasConceptScore W2980925570C143998085 @default.
- W2980925570 hasConceptScore W2980925570C150194340 @default.
- W2980925570 hasConceptScore W2980925570C185592680 @default.
- W2980925570 hasConceptScore W2980925570C190727270 @default.
- W2980925570 hasConceptScore W2980925570C197934379 @default.
- W2980925570 hasConceptScore W2980925570C2776239401 @default.
- W2980925570 hasConceptScore W2980925570C2776694085 @default.
- W2980925570 hasConceptScore W2980925570C2778041864 @default.
- W2980925570 hasConceptScore W2980925570C2778336483 @default.
- W2980925570 hasConceptScore W2980925570C2778461978 @default.
- W2980925570 hasConceptScore W2980925570C2778729363 @default.
- W2980925570 hasConceptScore W2980925570C2780235182 @default.
- W2980925570 hasConceptScore W2980925570C2780775027 @default.
- W2980925570 hasConceptScore W2980925570C2911091166 @default.
- W2980925570 hasConceptScore W2980925570C55493867 @default.
- W2980925570 hasConceptScore W2980925570C71924100 @default.
- W2980925570 hasConceptScore W2980925570C87355193 @default.
- W2980925570 hasLocation W29809255701 @default.
- W2980925570 hasOpenAccess W2980925570 @default.
- W2980925570 hasPrimaryLocation W29809255701 @default.
- W2980925570 hasRelatedWork W2166041313 @default.
- W2980925570 hasRelatedWork W2241382955 @default.
- W2980925570 hasRelatedWork W2550069662 @default.
- W2980925570 hasRelatedWork W2552161071 @default.
- W2980925570 hasRelatedWork W2553199911 @default.
- W2980925570 hasRelatedWork W2566918577 @default.
- W2980925570 hasRelatedWork W2570218122 @default.
- W2980925570 hasRelatedWork W2591763181 @default.
- W2980925570 hasRelatedWork W2594679250 @default.
- W2980925570 hasRelatedWork W2921388271 @default.
- W2980925570 hasRelatedWork W2979796411 @default.
- W2980925570 hasRelatedWork W2979820307 @default.
- W2980925570 hasRelatedWork W2980010047 @default.
- W2980925570 hasRelatedWork W2983485463 @default.
- W2980925570 hasRelatedWork W2992752643 @default.
- W2980925570 hasRelatedWork W3192739496 @default.
- W2980925570 hasRelatedWork W3198463471 @default.
- W2980925570 hasRelatedWork W3198544158 @default.
- W2980925570 hasRelatedWork W3212111143 @default.
- W2980925570 hasRelatedWork W378987734 @default.